GlassScriptPhysician profile
Jonathan A Jones
NPI 1043740418
$9,438.14
in general payments reported to CMS, 2019-2025
47 companies · $1,795 in 2025
The $1,795 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $149 · 2020: $428 · 2021: $1,455 · 2022: $1,482 · 2023: $1,624 · 2024: $2,505 · 2025: $1,795.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,924.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,923.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,616.50 | 2020-2025 | |
| Novo Nordisk INC | $909.47 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $900.20 | 2020-2025 | Breztri, Farxiga, Airsupra |
| Pfizer INC. | $872.34 | 2019-2025 | |
| Amgen INC. | $743.14 | 2020-2025 | Repatha, Otezla, Otezla |
| Ironwood Pharmaceuticals, INC | $511.99 | 2021-2025 | Linzess |
| Lilly USA, LLC | $389.18 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $362.70 | 2021-2025 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $324.98 | 2019-2025 | Jardiance, Synjardy, Ofev |
| Otsuka America Pharmaceutical, INC. | $307.75 | 2024-2025 | Rexulti |
| Abbott Laboratories | $287.06 | 2023-2024 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $273.02 | 2020-2025 | Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $161.52 | 2020-2023 | Verquvo |
| Exact Sciences Corporation | $151.17 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novartis Pharmaceuticals Corporation | $130.39 | 2023-2025 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.